-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 15, the Beijing Stock Exchange, which has received much attention, officially opened for trading.
A total of 81 "specialized, sophisticated, special, and new" companies became the first listed companies
.
In the medical and biological field, there are 10 companies that have moved to the Beijing Stock Exchange, including Datang Pharmaceutical, Sanyuan Gene, Biological Valley, Yongshun Biological, Senxuan Pharmaceutical, Northland, Deyuan Pharmaceutical, Lude Medical, Jinhao Medical, etc.
, cover multiple medical subdivisions such as western medicine, traditional Chinese medicine, biotechnology, medical and healthcare equipment
.
These 10 pharmaceutical companies are all focusing on R&D and innovation in their respective subdivisions
.
And most of them are giants in related segments
.
For example, Biology Valley is mainly committed to the research and development of drugs in the field of ischemic cardiovascular and cerebrovascular diseases, with the goal of becoming a giant in the field of ischemic cardiovascular and cerebrovascular diseases; Deyuan Pharmaceuticals is a company that focuses on drugs in the endocrine field.
A modern pharmaceutical company integrating R&D, production and sales.
It has been deeply involved in diabetes, diabetic complications, and cardiovascular disease medications for many years.
It has become a well-known enterprise in this field; Senxuan Pharmaceutical is a platform for the raw material medicine of Jinghua Pharmaceutical, and the company directly holds shares 72.
31%.
Its main business is the R&D, production and sales of APIs, pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates
.
At present, there are 19 types of API products, 3 types of pharmaceutical intermediate products and 2 types of chemical intermediate products, covering multiple fields such as anti-tumor, anti-bacterial, and anti-hypertensive products
.
On the whole, the 10 listed pharmaceutical and biological companies have relatively high R&D investment
.
Among them, the research and development expenses of Deyuan Pharmaceuticals in the first half of 2021 were 22,922,500 yuan, and the research and development expenses accounted for 9.
24% of operating income
.
At present, Deyuan Pharmaceuticals has 12 registration approvals for preparations, 2 registration approvals for APIs, and 3 APIs approved for use in marketed formulations
.
The industry believes that in the next 10 years, with the improvement of China's medical consumption, the iterative upgrade of drug varieties and the influence of medical insurance policy orientation, the prospect of China's diabetes drug market is very broad
.
According to the International Diabetes Federation (IDF), China's diabetes drug market will increase from 51.
2 billion yuan in 2017 to 97.
8 billion yuan in 2022, and will grow to 173.
9 billion yuan by 2028, a strong growth
.
Northland is followed by R&D expenses of RMB 1963.
26 million, and R&D expenses in the first half of 2021 accounted for 86.
01%
.
This is an innovative biopharmaceutical company specializing in the research and development, production and sales of gene therapy drugs, recombinant protein drugs and ophthalmic drugs
.
At present, the company is developing 12 new bioengineering drugs corresponding to 14 indications, and is carrying out 3 phase III clinical studies, 1 phase II clinical study, and the remaining 9 bioengineering innovative drug projects are in the preclinical research stage; in addition, as of 2021 On June 30, Northland has passed the GMP certification/inspection of 2 eye drop production lines, has obtained 3 eye drop product registration approvals, 1 eye drop product is under registration and approval, and many other eye drop chemistry The generic drug project is in the research and development stage
.
In addition to these two listed pharmaceutical companies, the research and development expenses of Senxuan Pharmaceutical and Yongshun Biological in the first half of the year were also more than 10 million yuan, and the proportion of operating income remained above 5% on average
.
From the perspective of corporate market value, as of November 9, the market value of the first 10 pharmaceutical companies listed on the Beijing Stock Exchange and the Shanghai and Shenzhen Main Board still have a certain gap in average market value
.
Among them, the company with a relatively high market value is Yongshun Biological, which amounts to 4.
663 billion yuan
.
The company is a biopharmaceutical enterprise integrating research and development, production, sales and technical services of veterinary biological products.
Its main products are vaccines for pigs and poultry.
The company achieved revenue of 286 million yuan in the first three quarters of this year, which is a return to mothers.
73.
64 million yuan
.
In addition, Jinhao Medical, whose market value is relatively small, is the first selected-tier company listed after the establishment of the Beijing Stock Exchange
.
The company is mainly engaged in the research and development, production and sales of rehabilitation medical equipment and home medical equipment.
The main products include hearing aids, atomizers, anti-decubitus cushions, etc.
, among which the hearing aid business contributed most of the company’s revenue, which accounted for the revenue in the past three years They are 62.
99%, 66.
37% and 73.
10% respectively
.
A total of 81 "specialized, sophisticated, special, and new" companies became the first listed companies
.
In the medical and biological field, there are 10 companies that have moved to the Beijing Stock Exchange, including Datang Pharmaceutical, Sanyuan Gene, Biological Valley, Yongshun Biological, Senxuan Pharmaceutical, Northland, Deyuan Pharmaceutical, Lude Medical, Jinhao Medical, etc.
, cover multiple medical subdivisions such as western medicine, traditional Chinese medicine, biotechnology, medical and healthcare equipment
.
These 10 pharmaceutical companies are all focusing on R&D and innovation in their respective subdivisions
.
And most of them are giants in related segments
.
For example, Biology Valley is mainly committed to the research and development of drugs in the field of ischemic cardiovascular and cerebrovascular diseases, with the goal of becoming a giant in the field of ischemic cardiovascular and cerebrovascular diseases; Deyuan Pharmaceuticals is a company that focuses on drugs in the endocrine field.
A modern pharmaceutical company integrating R&D, production and sales.
It has been deeply involved in diabetes, diabetic complications, and cardiovascular disease medications for many years.
It has become a well-known enterprise in this field; Senxuan Pharmaceutical is a platform for the raw material medicine of Jinghua Pharmaceutical, and the company directly holds shares 72.
31%.
Its main business is the R&D, production and sales of APIs, pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates
.
At present, there are 19 types of API products, 3 types of pharmaceutical intermediate products and 2 types of chemical intermediate products, covering multiple fields such as anti-tumor, anti-bacterial, and anti-hypertensive products
.
On the whole, the 10 listed pharmaceutical and biological companies have relatively high R&D investment
.
Among them, the research and development expenses of Deyuan Pharmaceuticals in the first half of 2021 were 22,922,500 yuan, and the research and development expenses accounted for 9.
24% of operating income
.
At present, Deyuan Pharmaceuticals has 12 registration approvals for preparations, 2 registration approvals for APIs, and 3 APIs approved for use in marketed formulations
.
The industry believes that in the next 10 years, with the improvement of China's medical consumption, the iterative upgrade of drug varieties and the influence of medical insurance policy orientation, the prospect of China's diabetes drug market is very broad
.
According to the International Diabetes Federation (IDF), China's diabetes drug market will increase from 51.
2 billion yuan in 2017 to 97.
8 billion yuan in 2022, and will grow to 173.
9 billion yuan by 2028, a strong growth
.
Northland is followed by R&D expenses of RMB 1963.
26 million, and R&D expenses in the first half of 2021 accounted for 86.
01%
.
This is an innovative biopharmaceutical company specializing in the research and development, production and sales of gene therapy drugs, recombinant protein drugs and ophthalmic drugs
.
At present, the company is developing 12 new bioengineering drugs corresponding to 14 indications, and is carrying out 3 phase III clinical studies, 1 phase II clinical study, and the remaining 9 bioengineering innovative drug projects are in the preclinical research stage; in addition, as of 2021 On June 30, Northland has passed the GMP certification/inspection of 2 eye drop production lines, has obtained 3 eye drop product registration approvals, 1 eye drop product is under registration and approval, and many other eye drop chemistry The generic drug project is in the research and development stage
.
In addition to these two listed pharmaceutical companies, the research and development expenses of Senxuan Pharmaceutical and Yongshun Biological in the first half of the year were also more than 10 million yuan, and the proportion of operating income remained above 5% on average
.
From the perspective of corporate market value, as of November 9, the market value of the first 10 pharmaceutical companies listed on the Beijing Stock Exchange and the Shanghai and Shenzhen Main Board still have a certain gap in average market value
.
Among them, the company with a relatively high market value is Yongshun Biological, which amounts to 4.
663 billion yuan
.
The company is a biopharmaceutical enterprise integrating research and development, production, sales and technical services of veterinary biological products.
Its main products are vaccines for pigs and poultry.
The company achieved revenue of 286 million yuan in the first three quarters of this year, which is a return to mothers.
73.
64 million yuan
.
In addition, Jinhao Medical, whose market value is relatively small, is the first selected-tier company listed after the establishment of the Beijing Stock Exchange
.
The company is mainly engaged in the research and development, production and sales of rehabilitation medical equipment and home medical equipment.
The main products include hearing aids, atomizers, anti-decubitus cushions, etc.
, among which the hearing aid business contributed most of the company’s revenue, which accounted for the revenue in the past three years They are 62.
99%, 66.
37% and 73.
10% respectively
.
